Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

Abstract Recently, the US Food and Drug Administration (FDA) approved the first chimeric antigen receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic leukemia. While CAR-T has achieved remarkable success in the treatment of hematopoietic malignancies, whether it...

Full description

Bibliographic Details
Main Authors: Jian Li, Wenwen Li, Kejia Huang, Yang Zhang, Gary Kupfer, Qi Zhao
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Journal of Hematology & Oncology
Subjects:
CAR-T
Solid tumor
Tumor microenvironment
Antigen recognition specificity
Safety control
Online Access:http://link.springer.com/article/10.1186/s13045-018-0568-6

Internet

http://link.springer.com/article/10.1186/s13045-018-0568-6

Similar Items